Semaglutide tablets 14mg

Description

Generic Name: Semaglutide
Brand Name: SEMAAP -14
Composition: Semaglutide……….14mg.

Indications:

• SEMAAP is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Dosage:

• Instruct patients to take SEMAAP at least 30 minutes before the first food, beverage, or other oral medications of the day with no more than 4 ounces of plain water only. Waiting less than 30 minutes, or taking with food, beverages (other than plain water) or other oral medications will lessen the effect of SEMAAP. Waiting more than 30 minutes to eat may increase the absorption of SEMAAP.

• Swallow tablets whole. Do not split, crush, or chew tablets.

• Start SEMAAP with 3 mg once daily for 30 days. After 30 days on the 3 mg dosage, increase the dosage to 7 mg once daily.

• Dosage may be increased to 14 mg once daily if additional glycemic control is needed after at least 30 days on the 7 mg dosage.

Contraindication:

• Personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2.

• Prior serious hypersensitivity reaction to semaglutide or any of the excipients in SEMAAP.

Warning:

• Pancreatitis: Has been reported in clinical trials. Discontinue promptly if pancreatitis is suspected. Do not restart if pancreatitis is confirmed.

• Diabetic Retinopathy Complications: Has been reported in a cardiovascular outcomes trial with semaglutide injection. Patients with a history of diabetic retinopathy should be monitored.

• Hypoglycemia: Concomitant use with an insulin secretagogue or insulin may increase the risk of hypoglycemia, including severe hypoglycemia. Reducing dose of insulin secretagogue or insulin may be necessary.

• Acute Kidney Injury: Monitor renal function in patients with renal impairment reporting severe adverse gastrointestinal reactions.

• Hypersensitivity Reactions: Serious hypersensitivity reactions (e.g., anaphylaxis and angioedema) have been reported. Discontinue SEMAAP if suspected and promptly seek medical advice.

• Acute Gallbladder Disease: If cholelithiasis or cholecystitis are suspected, gallbladder studies are indicated.

Adverse effects:

• Most common adverse reactions (incidence ≥5%) are nausea, abdominal pain, diarrhea, decreased appetite, vomiting, and constipation.

Dosage form: white tablets
Expiry date: 24 months after the date of manufacture
Packaging: 30 tablets per box
Storage:

• Protected from light, sealed, and stored at 20°C- 25°C.

• Keep out of reach of children.

Manufactured by: Asia Pharmaceuticals(Laos) Factory.
Location: Saysettha Development Zone, Vientiane Capital, Lao PDR